All news from R&D

Mosquito "Birth Control" By Protein Discovery

Researchers at the University of Arizona have discovered a way of preventing mosquito eggs from hatching, potentially paving the way for drugs that could serve as “birth control” within mosquito populations. Lead author Dr. Jun Isoe and colleagues hope the approach may provide a way of interrupting mosquito reproduction and reducing populations of the insects in areas of human disease transmission.

Feasibility of Developing Drug Delivery Vehicles

Aptamer Group announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney. The two-year agreement will give AstraZeneca use of Aptamer Group's proprietary technology to explore the feasibility of developing the next generation of drug delivery vehicles, called Aptamer Drug Conjugates (ApDCs).

'Zombie cells' Play Role in Anxiety: Findings

Mayo Clinic researchers and collaborators have shown that the obesity increases the level of "zombie" or senescent cells in the brain, and that those cells, in turn, are linked to anxiety. When senolytic drugs are used to clear those cells, the anxious behaviors in the mice dissipate. These findings appear in  Cell Metabolism .

Research: Phase III KATHERINE Trial Crossed Early Reporting Boundary

Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in patients who had residual disease after receiving neoadjuvant chemotherapy and trastuzumab reduced the risk of developing an invasive recurrence of HER2-positive early-stage breast cancer by 50%, according to data from the phase III clinical trial KATHERINE presented at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4-8.